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Abstract
Background: Malignant pleural mesothelioma (MPM) is a tumor known to be resistant to
conventional therapies. Thus, an in vivo model can represent an important tool for assessing the
efficacy of novel approaches in the treatment of MPM.
Presently, human MPM cells have been grown orthotopically in mice upon transplantation of tumor
masses or tumor cell suspensions following surgery. In these models however, surgery can
interfere with the tumor growth and the early stages of tumor development cannot be easily
explored. Finally, results may not be so accurate due to implantation of potentially different tumor
samples in different experimental groups.
Our work aimed at establishing a nude mouse model xenotransplanted with human MPM cell lines
in which tumor progression exhibits some features of the human disease.
Methods: Three distinct human MPM cell lines previously established from MPM patients
displaying two different phenotypes, biphasic (MM-B1 and IST-Mes3) and epithelioid (IST-Mes2),
were directly injected into the pleural cavity of nude mice. At different times, mice were sacrificed
for autopsy, tumor nodules were counted and then removed for histology. Presence of metastases
in visceral organs was also monitored.
Results: IST-Mes2 cells were unable to grow in nude mice. MM-B1 and IST-Mes3 cells were
capable of growing in nude mice and formed tumor nodules in the pleura. Post-mortem
examination showed that MPM cells progressively colonized the parietal and visceral pleura, the
diaphragm, the mediastinum and, lastly the lung parenchyma. No pneumo-thorax was evidenced in
the mice. Pleural effusions as well as lymph node metastases were observed only at later times.
Conclusion: This model mimics the progression of human malignant mesothelioma and it is easy
to perform and reproducible; therefore it can be useful to study human MPM biology and evaluate
the efficacy of novel therapies.
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Malignant pleural mesothelioma is a tumor of the pleura
mainly caused by exposure to asbestos fibers. MPM diag-
nosis regards about 2500 persons every year in the United
States [1] and the prognosis is poor despite the therapies
currently used, including surgery, radiotherapy and chem-
otherapy.
Because of the inefficacy of the conventional treatments,
novel therapeutic strategies are under investigation, with
particular attention devoted to agents capable of inhibit-
ing the angiogenesis or inducing tumor cell apoptosis [2-
7].
Tumor angiogenesis, apoptosis and metastasis, strictly
depend on the site of tumor development; therefore a
human-like animal model is an important tool for study-
ing new approaches for MPM treatment.
A number of evidences indicate that orthotopic models of
tumor growth are more valuable as compared to those in
which the tumor mass grows subcutaneously [8].
In regard to MPM, subcutaneous implantation of human
cancer cells in immunodeficient mice results in tumor
growth at the injection site and no metastatic dissemina-
tion, whereas human MPM growth in humans is associ-
ated with regional tumor spreading and lung invasion [9].
Presently, human MPM cells have been grow orthotopi-
cally in mice upon transplantation of tumor masses or
tumor cell suspensions following surgery [10]. In these
models however, surgery can interfere with the tumor
growth [8] and the early stages of tumor development
cannot be easily explored. Finally, results may be not so
accurate due to implantation of potentially different
tumor samples in different experimental groups [9]. Over-
all, the aim of this work was to establish a new orthotopic
tumor model by injecting human MPM cells directly into
the pleural cavity of nude mice. This model does not need
surgical operations, can be easily performed and more
importantly can mimic tumor development in humans.
Thus it can represent an useful tool for studying human




Human malignant pleura mesothelial cell lines were
established as previously described [11,12]. Three distinct
cell lines with two different phenotypes, biphasic (MM-B1
and IST-Mes3) and epithelioid (IST-Mes2) were used
between the eighth and twelfth passage in culture. Cells
were maintained in RPMI-1640 medium and 10% fetal
bovine serum, 1% L-glutamine and 1% penicillin-strepto-
mycin, (Euroclone, Devon, UK) at 37°C in a humidified
incubator in an atmosphere of 5% CO2 in air.
Animals
Athymic male nude mice nu/nu (Harlan, Italy), 6 week-
old were used. Mice were kept in laminar-flow cages in
standardized environmental conditions. Sterilized food
(Harlan, Italy) and water were supplied ad libitum.
Subcutaneous implantation of MPM cells in nude mice
Cells were harvested at near confluence with trypsin/
EDTA solution. Only cell suspensions with a viability of
>90% as assessed by trypan blue exclusion assay, were
used. Two × 106 MPM cells in 100 µl of Ca++ and Mg++
free Hank's balanced salt solution (HBSS) were injected
subcutaneously on the left lateral chest wall near to the
axilla. Tumor growth was monitored twice a week using a
caliper. Tumor volume was calculated using the formula:
V (mm3) = (D × d2)/2, where d (mm) and D (mm) are
the smallest and largest perpendicular tumor diameter,
respectively.
Orthotopic implantation of MPM cells in nude mice
Mice were anaesthetized with Tiletamine chlorohydrate
and Zolazepam chlorohydrate and placed in position of
right lateral decubitus. A 27 gauge needle of a 1000 µl
syringe was advanced approximately through the fourth
intercostal space for about 5 mm, into the left pleural cav-
ity, and two × 106 tumor cells suspended in 100 µl of
HBSS were injected. The site of injection in the chest and
the precise depth of the needle tip required to reach the
pleural space were previously determined by injecting cre-
syl violet. A primary tumor cell line IST-Mes3/2P (IST-
Mes3/2nd Passage) was established from a IST-Mes3
tumor grown orthotopically. Tumors were grounded into
small pieces in RPMI-1640 and digested with trypsin/
EDTA solution. The cell suspension was then plated in a
75 ml culture flask and the following day, non adherent
cells were removed. Cells were maintained in culture, and
2 × 106 cells were injected into the pleural cavity of nude
mice when devoid of fibroblasts or endothelial cells.
Therapeutic procedures
Four groups of animals were used. The first group of ani-
mals were used to analyze the tumorigenicity of MPM cell
lines after orthotopic or subcutaneous implantation in
nude mice. Animals were then injected with MPM cells as
reported in Table 1.
The second, third and fourth groups were used to analyze
the growth rate of IST-Mes3, IST-Mes3/2P and MM-B1
cells respectively after orthotopic implantation in mice.Page 2 of 7
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Mice were sacrificed at different times following tumor
cell injection as specified.
Tumor nodules were counted, measured with the caliper,
removed, immediately snap frozen in liquid nitrogen and
stored at -80°C. The presence of metastasis in the visceral
organs was macroscopically checked.
Immunohistochemistry
Microvessel density (MVD) was determined by using the
endothelial cell marker CD31. Tumors were placed in
OTC compound and snap frozen in liquid nitrogen and
stored at -80°C. Frozen section (10–20 µm) were fixed
with cold acetone (5 min), acetone/chlorophorm 1/1 (5
min) and cold acetone (5 min). Samples were then rinsed
with PBS/Triton 1%, and treated with 3% hydrogen per-
oxide in methanol (vol/vol). Slides were incubated in a
blocking solution and then overnight at 4°C in a humid-
ified chamber with a rat anti-mouse CD31 monoclonal
antibody (BD Biosciences Pharmingen, NJ, USA). Thereaf-
ter, slides were rinsed with PBS and incubated, first with
the blocking solution for 20 min and then with a biotin-
conjugated goat anti-rat antibody (Santa Cruz Biotechnol-
ogy, CA, USA) for 1 h. Slides were then rinsed with PBS
and incubated for 30 min with the Vector Vectastain ABC
Kit (Vinci-Biochem, Vinci, FI). After 3 washes with PBS,
positive reactions were visualized by incubating the slides
for 5 min with stable DAB (Sigma, Italy). Slides were dried
and mounted with Universal Mount.
For mesothelioma markers, 3–4 µm paraffin tumor sec-
tions were float mounted on poly-L lysine coating slides,
deparaffinized in xylene and rehydrated in a descending
ethanol series. Anti-Ber-EP4 monoclonal antibody
required enzymatic pre-treatment of the slides with 0.1%
trypsin (Sigma, St. Louis, MO) for 10 min at 37°C; for the
other antibodies, slides were not enzimatically pre-
treated, but they were placed in 0.1 M citrate buffer (pH
6.0) and boiled for 10 min in a microwave oven at 750 W
to enhance antigenicity. Slides were washed in phosphate
buffer and incubated for 10 min in 0.3% hydrogen perox-
ide to quench endogenous peroxidase activity. Slides were
then loaded onto a LabVision automated immunostainer
(NeoMarkers, Fremont, CA) and sequentially incubated
with intervening washes in PBS for 5 min, with 10% oval-
bumin for 15 min to reduce non-specific background
staining, primary antibody for 60 min at room tempera-
ture, the appropriate biotinylated linking antibody (Neo-
Markers, Fremont, CA) for 10 min, peroxidase-labeled
streptavidin (NeoMarkers, Fremont, CA) for 10 min, and
finally with 3,3'-diaminobenzidine chromogen substrate
for 10 min. Slides were then thoroughly rinsed in distilled
water and counterstained with Mayer's haematoxylin,
dehydrated, cleared in xylene and finally mounted in
Entellan. Appropriate positive and negative controls were
included for each marker. A panel of eight markers was
used. Mouse anti-human antibodies included anti-CEA
(dilution 1:100; NeoMarkers, Fremont, CA), polyclonal
anti-calretinin (dilution 1:1000; NeoMarkers, Fremont,
CA), monoclonal anti-CD15 (Leu-M1) (dilution 1:4; Bec-
Table 2: Growth progression of IST-Mes3 cell line after orthotopic implantation in nude mice.
Days after implantation <56 60 65 71 73 80 87 94 98
N° of animals with tumor nodules1 0/5 1/5 2/5 1/5 1/5 0/5 1/5 1/5 2/5
N° of tumor nodules detected in each animal - >20 >20 >20 >20 - >20 >20 >20
2 × 106 IST-Mes3 cells were injected into the pleural cavity of nude mice. Five animals were sacrificed when they became dyspneic or at indicated 
times and tumor nodules were counted, measured, removed and frozen for immunohistochemical analysis. Data shown report tumor development 
in individual animals.
Table 1: Tumorigenicity of MPM cell lines after orthotopic and subcutaneous implantation in nude mice.
Cell line Histology Tumorigenicity Implantation method Survival(days) (mean ± SD) Survival (days) (Min/Max)
IST-Mes2 Epithelioid 0/15 Orthotopic - -
Epithelioid 0/15 Subcutaneous - -
IST-Mes3 Biphasic 15/15 Orthotopic 81,5 ± 21,7 60/122
Biphasic 15/15 Subcutaneous Sacrificed after 90 days -
IST-Mes3/2P Biphasic 15/15 Orthotopic 69,6 ± 14,5 54/89
MM-B1 Biphasic 15/15 Orthotopic 72,5 ± 6,4 68/77
Biphasic 0/15 Subcutaneous - -
2 × 106 MPM cells were injected into the pleural cavity of nude mice. The experiment ended when mice were moribund.Page 3 of 7
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1:100; NeoMarkers, Fremont, CA), monoclonal anti-
cytokeratin 8 and 18 (dilution 1:50; Biomeda, Foster City,
CA), monoclonal anti-EMA (dilution 1:500; NeoMarkers,
Fremont, CA). monoclonal anti-mesothelioma (HBME-1)
(dilution 1:25; NeoMarkers, Fremont, CA), monoclonal
anti-podoplanin (dilution 1:50; Serotec, Dusseldorf, Ger-
many).
Hematoxylin-and-eosin staining
Tumors were placed in OTC compound and snap frozen
in liquid nitrogen and stored at -80°C. Frozen section
(10–20 µm) were fixed with cold acetone (5 min), ace-
tone/chlorophorm 1/1 (5 min), cold acetone (5 min).
Slides were then rinsed with water for10 min, stained with
Mayer's Hematoxylin Solution for 10 min (Sigma, St.
Louis, MO), rinsed with water for 10 min and then stained
with eosin 0.5% for 30 sec (Sigma, St. Louis, MO). Slides
were then dehydrated through 95% alcohol (5 min.) and
2 changes of absolute alcohol, 5 min each, cleared in 2
changes of xylene (5 min) and finally mounted with
xylene based mounting medium.
Results
Growth of human MPM cells in nude mice
Human MPM cell lines were tested for their ability to form
tumors after intrapleural and subcutaneous injection in
nude mice. Table I summarizes the tumor take rates of
these cell lines. Tab. II, and III summarize the growth rate
of these cell lines after orthotopic implantation, whereas
Fig. 1. shows their growth rate following subcutaneous
implantation. IST-Mes2 cells were unable to grow in nude
mice. By contrast, 2 × 106 IST-Mes3 or MMB-1 tumor cells
had a take-rate of 100 % when injected into the left pleu-
ral cavity. The mean survival time was of 72.5 ± 6.4 days
for mice injected with MM-B1 cells; 81.5 ± 21.7 days for
mice injected with the IST-Mes3 cells and 69.6 ± 14.5 days
for mice injected with the IST-Mes3/2P cells. These mice
were sacrificed when moribund, or at different times after
cell injection as specified in Tab. I, II, III and IV. Animals
injected with the IST-Mes3 cells were analyzed when they
became dyspneic because of the tumor growth rate varies
from animal to animal. These variations were not
observed upon in vitro culture of IST-Mes3 tumor as
shown by the analysis of the growth rate of IST-Mes3/2P
cells. Tumor cells grew on both sides of parietal and vis-
ceral pleura, diaphragm and mediastinum; at later times,
tumor invasion into lung parenchyma was observed (Fig.
2, 3). No pneumothorax was evidenced in the mice. Pleu-
ral effusions as well as lymph node metastasis were noted
only in the later stages of orthotopic growth of MM-B1,
IST-Mes3 and IST-Mes3/2P cells. MM-B1 and IST-Mes2
cells did not grow when injected subcutaneously. IST-
Mes3 cells started to grow only at forty days after tumor
cell injection. This lag phase was independent on the
number of cells injected (Fig. 1).
Immunohistochemical analysis
MPM cells were injected into pleura cavity of nude mice
and tumor samples were collected for immunohisto-
Table 4: Growth progression of MM-B1 cell line after orthotopic implantation in nude mice.
Days after implantation 38 45 52 59 66 73
Mediastinum nodules < 101 10–201 10–202 10–202 >203 >203
Pericardium nodules < 101 10–201 10–202 10–202 >203 >203
Parietal Pleura nodules - - - 10–202 >203 >203
Lungs nodules - - - 10–202 >203 >203
Diaphragms nodules - - - - - -
2 × 106 MM-B1 cells were injected into the pleural cavity of nude mice. At indicated times, mice were sacrificed and tumor nodules were counted, 
measured, removed and frozen for immunohistochemical analysis. Data shown are mean of 5 mice.
1 Nodule diameter ≤ 1 mm; 2 Nodule diameter 2–3 mm; 3 Nodule diameter ≥ 3 mm. No nodules were found before the days indicated in the table.
Table 3: Growth progression of IST-Mes3/2P cell line after orthotopic implantation in nude mice.
Days after implantation 54 61 68 75 82 89
Mediastinum nodules < 101 <102 <103 <103 10–203 10–203
Pericardium nodules < 101 <102 <103 <103 10–203 10–203
Parietal Pleura nodules < 101 <102 <103 <103 10–203 10–203
Lungs nodules - - - <102 <102
Diaphragms nodules - - - - <102 <102
2 × 106 IST-Mes3/2P cells were injected into the pleural cavity of nude mice. At indicated times mice were sacrificed and tumor nodules were 
counted, measured, removed and frozen for immunohistochemical analysis. Data shown are mean of 5 mice.
1 Nodule diameter ≤ 1 mm; 2 Nodule diameter = 2–3 mm; 3 Nodule diameter ≥ 3. No nodules were found before the days indicated in the table.Page 4 of 7
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mass was highly vascularized (Fig. 3). For the phenotypic
characterization of tumor mass, a panel of eight markers
was used (Tab. 5). Recent findings showed that Mesothe-
lin and TTF-1 have a limited value in assisting in the diag-
nosis of Mesothelioma and therefore were not used
[13,14]. CEA and BerEP4 are adenocarcinoma specific
markers and therefore are nor expressed by mesotheli-
oma. Calretinin and HBME-1 are positive markers shared
by both epithelioid and biphasic variants of mesotheli-
oma, whereas CD15 is a negative marker. Surface expres-
sion of the epithelial membrane antigen (EMA) is a
marker that discriminates between reactive proliferation
of mesothelial cells and malignant mesothelioma. The
epithelia of biphasic mesotheliomas show strong reactiv-
ity for Cytokeratin 8/18, whereas Podoplanin is the most
recently recognized marker for epithelioid mesothelio-
mas.
Discussion
New strategies for MPM treatment, which include inhibi-
tion, of angiogenesis, induction of tumor cell apoptosis,
gene therapy and vaccines [15], need clinically represent-
ative animal models to test new drugs and explore tumor
biology.
In this work we established a non invasive orthotopic
model of human MPM by injecting the cancer cells
directly into the pleural cavity of nude mice. The charac-
teristics of tumor growth resemble those observed in
tumor-bearing patients, with colonization of parietal and
visceral pleura, diaphragm, mediastinum and, at later
stages, lung parenchyma. We analyzed the tumorigenicity
of three different human MPM cell lines, which exhibited
different biological behaviors in vivo. Interestingly, the
growth of MM-B1 cells seems to be site-specific as they did
not form tumor masses when injected subcutaneously.
Differently, the IST-Mes3 cells grow subcutaneously with
a latency which does not depend on the number of cells
injected (Fig. 1). This resembles some human situations
in which cancer cells start to grow exponentially and form
manifest tumor masses only after a long period of time
from the acquisition of the tumorigenic phenotype.
As previously reported, neo-angiogenesis is an important
process in MPM and protocols to inhibit this process are
currently under investigation. Our model can be useful to
study angiogenesis in MPM as tumors displayed high den-
sity of micro-vessels. IST-Mes3 tumor grew with a latency
of 60 days and this period remained substantially con-
stant after tumor passage in mice. All the cell lines tested
were unable to form metastases in the visceral organs,
likely due to lack of time for tumor dissemination as the
rapid spreading of the tumor cells into the pleural cavity
dramatically resulted in mouse death. Among the cell
lines tested, the MM-B1 cells seem to be the more appro-
priate for drug evaluation. In fact, as shown in Tab. II, the
IST-Mes3 cells grow very rapidly to follow the progression
of the disease, colonizing the entire pleural cavity and dra-
matically affecting the physical conditions of the mice
which become cachectic and dyspneic, and the latency of
tumor takes varies from animal to animal. The results
obtained with the IST-Mes3/2P cell show that these varia-
Pleural MPM nodulesFigure 2
Pleural MPM nodules. IST-Mes3 cells (2 × 106 in 100 µl of 
HBSS) were injected into the left pleural cavity of nude mice. 
Tumor masses completely invaded the thoracic and visceral 
pleural and the lungs. The irregular growth of this cell line is 
evidenced by a major bulk of tumor in the right chest.
Subcutaneous growth of MPM cellsFigure 1
Subcutaneous growth of MPM cells. Subcutaneously 
growth of MPM cells in nude mice.  = IST-Mes3 (2 × 106 
cells injected), ■ = IST-Mes3 (4 × 106 cells injected), ▲ = 
IST-Mes2 (2 × 106 cells injected), ●  = MM-B1 (2 × 106 cells 
injected). Tumor volume was calculated using the formula: V 
(mm3) = (D × d2)/2, where d (mm) and D (mm) are the 
smallest and largest perpendicular tumor diameters, respec-
tively.Page 5 of 7
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tured in vitro.
The growth rate of MM-B1 cells is reproducible. Tumors
develop in all animals with a similar latency and the rate
of tumor growth is slow enough to follow the progression
of the disease. In this context, a noninvasive imaging
methodology would be a useful tool to follow tumor
development.
IST-Mes2 cells did not grow in nude mice, but, since the
epithelioid phenotype is the most common sub-type of
mesothelioma, we plan to set up an orthotopic model
using different ephitelioid cells.
Immunohistochemistry of tumors growing in the nude
mice showed that MM-B1 and IST-Mes3 cells maintained
the mesothelioma-specific characteristics, thus confirm-
ing the validity of the orthotopic model here established.
Conclusion
Overall, this work describes the biological behavior of
human MPM cells injected in the pleural cavity of nude
mice. Because of the similarity of this orthotopic model
with the human disease, the simplicity of execution and
the reproducibility of the results, we propose this model
as an useful tool for in vivo MPM studies.
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